<DOC>
	<DOCNO>NCT00413686</DOCNO>
	<brief_summary>This open-label , multi-center , dose-escalation , Phase I study evaluate safety , tolerability , pharmacokinetics investigate biomarker change AZD7762 administer single intravenous unit combination gemcitabine . The study sponsor AstraZeneca .</brief_summary>
	<brief_title>Study Assess Safety AZD7762 Administered Alone Combination With Gemcitabine Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologically cytologically confirm malignancy metastatic unresectable standard curative palliative measure exist longer effective ECOG performance status 0 1 Patient tumor type must suitable treatment weekly standard gemcitabine . Inadequate bone marrow reserve , inadequate liver function impair renal function Any troponin elevation ( normal range ) Stage II , III , IV cardiac status , accord New York Heart Association ( NYHA ) classification ; recent history ( ie , within 6 month ) coronary artery disease arteriosclerotic cardiovascular disease ( angina , myocardial infarction [ MI ] ) Any prior anthracycline treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Mixed solid tumor</keyword>
</DOC>